More great news for Clinuvel. Another competitor dropping right...

More great news for Clinuvel. Another competitor dropping right off after Phase 2 results in an EPP study showed their drug didn't have any statistically significant increase for time in sun over the placebo, back to the drawing board and good luck trying to recruit subjects in the future in this rare disease. Meanwhile the CUV safe and effective drug with 95% retention will maintain a monopoly for many years and might even be able to pick up subjects from Disc and MT trials who want to finally get onto some approved treatment that works and might even give some other nice benefits on top of being able to live a normal life in the sun eg liver repair as one study showed.

Amazingly Disc still valued nearly double CUV with a market cap ~ $1.3 Billion AUD! The shorters have really devalued CUV a lot and hopefully the buyback starts to address this manipulation issue, maybe some disgruntled Disc investors will come to CUV the risk/reward play would seem to be much, much better. After all Clinuvel is already running a Phase 3 with an FDA, EMA approved and safe drug into a blockbuster indication which IMO will be approved before they could even hope to complete a Phase 3 into EPP.

Good feeling that things are looking up here, forward earnings and risk/reward here pretty much unmatched IMO with Vitiligo not priced-in at all or anything else for that matter.

All IMO DYOR